Description: Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. The company was incorporated in 2014 and is headquartered in San Diego, California.
Home Page: reneopharma.com
RPHM Technical Analysis
18575 Jamboree Road
Irvine,
CA
92612
United States
Phone:
858 283 0280
Officers
| Name | Title |
|---|---|
| Mr. Michael G. Grey | Founder & Exec. Chairman |
| Mr. Gregory J. Flesher | Pres, CEO & Director |
| Mr. Michael P. Cruse | Chief Operating Officer |
| Mr. Vineet R. Jindal | Consultant |
| Ms. Jennifer P. Lam | Principal Financial & Accounting Officer |
| Ms. Wendy S. Johnson M.B.A. | Consultant |
| Dr. Alejandro Dorenbaum M.D. | Chief Medical Officer |
| Ms. Lynn Purkins Ph.D. | Sr. VP of Clinical Operations |
| Ms. Ashley F. Hall J.D. | Chief Devel. Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4685 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-04-08 |
| Fiscal Year End: | December |
| Full Time Employees: | 32 |